awarded Sumagen Canada Inc. a financial contribution of up to $728,000 to support their
human clinical trials for the preventative HIV/AIDS vaccine on Friday (Jan.12).
The tests are based on genetically modified ‘killed whole virus’, called SAV001.United States
Food and Drug Administration (FDA) last December gave approval to Sumagen Canada to
start the first of three phases of clinical trials.
The preliminary studies showed no adverse effects or safety risks, during test it was also
found that the HIV vaccine stimulate strong immune responses, the tests was undertaken at
University of Western Ontario. Canada is one of few countries were the development of such
kind in HIV vaccine has been undertaken.
Sumagen Canada is getting a huge assistance from NRC-IRAP under The Canadian HIV
Technology Development (CHTD) Program and Bill and Melinda Gates foundation to test the
safety of the clinical trail of first of three phases which is going to start in this month.
Canadian HIV Initiative (CHVI) initiates CHTD Program which is a partnership between
Melianda Gates foundation and Government of Canada.
28 million people have been killed due HIV/AIDS virus worldwide, and at present 35 million
people are living with the virus. Pharmaceutical companies and academic institutions all
over the world have made numerous trials since 1983 when the virus was first typified. Till
now no commercialized vaccine has been made.
Till now the vaccines that have been developed focuses on recombinant viruses carrying the
HIV genes or it concentrates on specific elements of HIV.
No comments:
Post a Comment